SBFM Stock Overview
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.
Sunshine Biopharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.24|
|52 Week High||US$29.80|
|52 Week Low||US$1.03|
|1 Month Change||8.77%|
|3 Month Change||-38.00%|
|1 Year Change||-95.19%|
|3 Year Change||-86.52%|
|5 Year Change||-99.82%|
|Change since IPO||-100.00%|
Recent News & Updates
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Sunshine Biopharma reports 1H results
Sunshine Biopharma press release (NASDAQ:SBFM): 1H Revenue of $0.27M. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021.
Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Sunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in with the CEO. The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement. Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.
|SBFM||US Biotechs||US Market|
Return vs Industry: SBFM underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: SBFM underperformed the US Market which returned -11.7% over the past year.
|SBFM Average Weekly Movement||14.1%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: SBFM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: SBFM's weekly volatility has decreased from 38% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.
Sunshine Biopharma, Inc. Fundamentals Summary
|SBFM fundamental statistics|
Is SBFM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SBFM income statement (TTM)|
|Cost of Revenue||US$215.32k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.27|
|Net Profit Margin||-1,260.23%|
How did SBFM perform over the long term?See historical performance and comparison